TerminatedPhase 3NCT02725372
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bellerophon Pulse Technologies
- Principal Investigator
- Ashika Ahmed, MDBellerophon Therapeutics
- Intervention
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr(drug)
- Enrollment
- 207 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2016 – 2018
Study locations (30)
- Arizona Pulmonary Specialists, Ltd, Phoenix, Arizona, United States
- University of Arizona Sarver Heart Center, Tucson, Arizona, United States
- Cedars-Sinai Medical Center, Beverly Hills, California, United States
- UC San Diego / Pulmonary, Critical Care and Sleep Medicine Division, La Jolla, California, United States
- West Los Angeles VA Healthcare Center, Los Angeles, California, United States
- University of California, Davis Medical Center, Sacramento, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- Pulmonary Disease Specialists, PA, Kissimmee, Florida, United States
- Central Florida Pulmonary Group, PA, Orlando, Florida, United States
- Cleveland Clinic Florida, Weston, Florida, United States
- Pulmonary and Critical Care of Atlanta, Atlanta, Georgia, United States
- Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States
- Wellstar Medical Group - Pulmonary Medicine, Marietta, Georgia, United States
- Bluhm Cardiovascular Institute, Clinical Trials Unit, Chicago, Illinois, United States
- HeartCare Midwest, Peoria, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Worldwide Clinical Trials
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02725372 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
- RECRUITINGNCT07013149The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNCT06998329PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArchUniversity of Sao Paulo General Hospital
- ENROLLING BY INVITATIONPHASE2NCT06992440Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionGustavo A Heresi, MD, MS
- RECRUITINGNANCT06968962Comparison of Sequential to Initial Combination Therapy in PAHSecond Affiliated Hospital, School of Medicine, Zhejiang University
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →